Department of Dermatology and Venereology, Hamad Medical Corporation, Doha, Qatar; Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar; Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar; Department of Dermatology, Weill Cornell Medicine-Qatar, Doha, Qatar; Qatar University, College of Medicine, Doha, Qatar; Department of Dermatology, Weill Cornell Medicine, New York, NY.
Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar; Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
J Allergy Clin Immunol. 2022 Jun;149(6):1875-1898. doi: 10.1016/j.jaci.2022.03.010. Epub 2022 Mar 23.
Atopic dermatitis (AD) is a common, chronic-relapsing inflammatory skin disease with significant disease burden. Genetic and environmental trigger factors contribute to AD, activating 2 of our largest organs, the nervous system and the immune system. Dysregulation of neuroimmune circuits plays a key role in the pathophysiology of AD, causing inflammation, pruritus, pain, and barrier dysfunction. Sensory nerves can be activated by environmental or endogenous trigger factors, transmitting itch stimuli to the brain. On stimulation, sensory nerve endings also release neuromediators into the skin, contributing again to inflammation, barrier dysfunction, and itch. In addition, dysfunctional peripheral and central neuronal structures contribute to neuroinflammation, sensitization, nerve elongation, and neuropathic itch, thus chronification and therapy resistance. Consequently, neuroimmune circuits in skin and central nervous system may be targets to treat pruritus in AD. Cytokines, chemokines, proteases, lipids, opioids, and ions excite/sensitize sensory nerve endings, which not only induces itch but further aggravates/perpetuates inflammation, skin barrier disruption, and pruritus as well. Thus, targeted therapies for neuroimmune circuits as well as pathway inhibitors (eg, kinase inhibitors) may be beneficial to control pruritus in AD either in systemic and/or in topical form. Understanding neuroimmune circuits and neuronal signaling will optimize our approach to control all pathological mechanisms in AD, inflammation, barrier dysfunction, and pruritus.
特应性皮炎(AD)是一种常见的慢性复发性炎症性皮肤病,具有显著的疾病负担。遗传和环境触发因素促成 AD 的发生,激活我们最大的两个器官,即神经系统和免疫系统。神经免疫回路的失调在 AD 的病理生理学中起着关键作用,导致炎症、瘙痒、疼痛和屏障功能障碍。感觉神经可以被环境或内源性触发因素激活,将瘙痒刺激传递到大脑。在受到刺激时,感觉神经末梢也会将神经递质释放到皮肤中,再次导致炎症、屏障功能障碍和瘙痒。此外,功能失调的周围和中枢神经元结构导致神经炎症、致敏、神经伸长和神经病理性瘙痒,从而导致慢性化和治疗抵抗。因此,皮肤和中枢神经系统中的神经免疫回路可能是治疗 AD 瘙痒的靶点。细胞因子、趋化因子、蛋白酶、脂质、阿片类物质和离子会兴奋/敏化感觉神经末梢,这不仅会引起瘙痒,还会进一步加重/持续炎症、皮肤屏障破坏和瘙痒。因此,针对神经免疫回路的靶向治疗以及途径抑制剂(如激酶抑制剂)可能有益于以全身和/或局部形式控制 AD 中的瘙痒。了解神经免疫回路和神经元信号将优化我们控制 AD 中所有病理机制、炎症、屏障功能障碍和瘙痒的方法。